The primary amine metabolite of sibutramine stimulates lipolysis in adipocytes isolated from lean and obese mice and in isolated human adipocytes

Hormone and Metabolic Research

Volumn 38, Issue 11, 2006, Pages 727-731

  Richardson, D K ^a   Jones, R B ^b   Bailey, C J ^c  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b ABBOTT LABORATORIES   (United States)

^c ASTON UNIVERSITY   (United Kingdom)

Author keywords

adrenoceptors; Lipolysis; M2; Sibutramine; White adipose tissue

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 1 [1 (4 CHLOROPHENYL)CYCLOBUTYL] 3 METHYL 1 METHYLAMINOBUTANE; 1 AMINO 1 [1 (4 CHLOROPHENYL)CYCLOBUTYL] 3 METHYLBUTANE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; AMINE; ATENOLOL; GLYCEROL; ISOPRENALINE; PRAZOSIN; PROPANOL; SIBUTRAMINE; YOHIMBINE;

ADIPOCYTE; ADRENERGIC SYSTEM; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INCUBATION TIME; LIPOLYSIS; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; OBESITY; PRIORITY JOURNAL; WHITE ADIPOSE TISSUE;

ADIPOCYTES; ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ADULT; AMINES; ANIMALS; APPETITE DEPRESSANTS; CELL SEPARATION; CYCLOBUTANES; FEMALE; GLYCEROL; HUMANS; LIPOLYSIS; MALE; MICE; MIDDLE AGED; OBESITY; OMENTUM;

MURINAE;

EID: 33845367675     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-955083     Document Type: Article

References (26)

1. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532-546
2. Day C, Bailey CJ. Sibutramine update. Brit J Dia. Vasc Dis 2002; 2: 392-397
3. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005; 21: 457-468
4. Tankova T, Dakovska G, Lazarova M, Dakovska L, Kirilov G, Koev D. Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. Acta Diabetol 2004; 41: 146-153
5. Ryan DH. Clinical use of sibutramine. Drugs Today (Barc) 2004; 40: 41-54
6. Finer N. Sibutramine: its mode of action and efficacy. Int J Obes Relat Metab Disord 2002; 26: 29-33
7. Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care 2005; 28: 942-949
8. McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998; 56: 1093-1124
9. Bailey CJ, Turner SL, Bates SH, Jones RB. Sibutramine metabolites increase glucose transport by cultured rat muscle cells. Int J Obes Relat Metab Disord 2001; 25: 478-485
10. Liu YL, Heal DJ, Stock MJ. Mechanism of the thermogenic effect of Metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine. Int J Obes Relat Metab Disord 2002; 26: 1245-1253
11. Liu YL, Connoley IP, Harrison J, Heal DJ, Stock MJ. Comparison of the thermogenic and hypophagic effects of sibutramine's metabolite 2 and other monoamine reuptake inhibitors. Eur J Pharmacol 2002; 452: 49-56
12. Day C, Bailey CJ. Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. Int J Obes Relat Metab Disord 1998; 22: 619-623
13. Flatt PR, Bailey CJ. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 1981; 20: 573-577
14. Bailey CJ, Flatt PR, Atkins TW. Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int J Obes 1982; 6: 11-21
15. Rodbell M. Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 1964; 239: 375-380
16. Pederson O, Hjollund E, Beck-Nielson H, Linskov H, Sonne H, Gliemann J. Insulin receptor binding and receptor mediated insulin degradation in human adipocytes. Diabetologia 1981; 20: 636-641
17. Wieland O. Glycerol UV method. In: Bergmeyer HU (ed). Methods of Enzymatic Analysis. London: Academic Press, 1974; 1404-1409
18. Jackson HC, Needham AM, Hutchins LJ, Mazurkiewicz SE, Heal DJ. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br J Pharmacol 1997; 121: 1758-1762
19. Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 1998; 22: 18-28
20. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB. Sibutramine produces dose-related weight loss. Obes Res 1999; 7: 189-198
21. Chapelot D, Marmonier C, Thomas F, Hanotin C. Modalities of the food intake-reducing effect of sibutramine in humans. Physiol Behav 2000; 68: 299-308
22. Barkeling B, Elfhag K, Rooth P, Rossner S. Short-term effects of sibutramine (Reductil) on appetite and eating behaviour and the long-term therapeutic outcome. Int J Obes Relat Metab Disord 2003; 27: 693-700
23. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998; 68: 1180-1186
24. Guo A, Johnson M, Jensen MD. Regional lipolytic responses to isoproterenol in women. Am Physiol Soc 1997; 273: 108-112
25. Galitzky J, Reverte M, Portillo M, Carpene C, Lafontan M, Berlan M. Coexistence of beta 1-, beta 2-, and beta 3-adrenoceptors in dog fat cells and their differential activation by catecholamines. Am J Physiol 1993; 264: 403-412
26. Dujovne CA, Zavoral JH, Rowe E, Mendel CM. Sibutramine Study Group. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am Heart J 2001; 142: 489-497